Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis

Hassan M. Fathallah-Shaykh, Li Juan Zhao, Abdallah I. Kafrouni, George M. Smith, James Forman

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The experiments in this paper were designed to examine the therapeutic effects of adenoviral-mediated gene transfer of IFN-γ into a mouse model of an established metastatic brain tumor. Temperature-sensitive replication- defective adenovirus was generated for gene transfer of IFN-γ (AdIFN) and β-galactosidase (AdBGAL) cDNAs in vivo. In this model, treatment with AdIFN elicits prolonged survival times and brain tumor rejection. Evidence against an immune-mediated response accounting for this result include: 1) absence of a memory immune response upon challenge, 2) lack of antitumor effects at sites distal to inoculation of AdIFN, and 3) preservation of the therapeutic effects of AdIFN in scid and beige mice and in inducible NO synthase (iNOS) knockouts. High concentrations of IFN-γ do not inhibit tumor growth in vitro making it unlikely that the antitumor effect of this treatment acts directly on the growth of the tumor cells. However, gene transfer of IFN-γ inhibits neovascularization of the tumor in a 3LL-Matrigel assay in vivo, and AdIFN induces apoptosis of endothelial cells in vivo, supporting the idea that AdIFN represses tumor growth by inhibiting angiogenesis. The substantial non- immune-mediated therapeutic benefits of AdIFN in animals paves the way for devising novel strategies for treating human brain tumors.

Original languageEnglish (US)
Pages (from-to)217-222
Number of pages6
JournalJournal of Immunology
Volume164
Issue number1
StatePublished - Jan 1 2000

Fingerprint

Brain Neoplasms
Therapeutic Uses
Growth
Genes
Neoplasms
Galactosidases
Adenoviridae
Nitric Oxide Synthase
Endothelial Cells
Complementary DNA
Apoptosis
Temperature
Survival
Transfer (Psychology)
Therapeutics

ASJC Scopus subject areas

  • Immunology

Cite this

Fathallah-Shaykh, H. M., Zhao, L. J., Kafrouni, A. I., Smith, G. M., & Forman, J. (2000). Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis. Journal of Immunology, 164(1), 217-222.

Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis. / Fathallah-Shaykh, Hassan M.; Zhao, Li Juan; Kafrouni, Abdallah I.; Smith, George M.; Forman, James.

In: Journal of Immunology, Vol. 164, No. 1, 01.01.2000, p. 217-222.

Research output: Contribution to journalArticle

Fathallah-Shaykh, HM, Zhao, LJ, Kafrouni, AI, Smith, GM & Forman, J 2000, 'Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis', Journal of Immunology, vol. 164, no. 1, pp. 217-222.
Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, Smith GM, Forman J. Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis. Journal of Immunology. 2000 Jan 1;164(1):217-222.
Fathallah-Shaykh, Hassan M. ; Zhao, Li Juan ; Kafrouni, Abdallah I. ; Smith, George M. ; Forman, James. / Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis. In: Journal of Immunology. 2000 ; Vol. 164, No. 1. pp. 217-222.
@article{77279ca6cdd542a1b6209f5014987785,
title = "Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis",
abstract = "The experiments in this paper were designed to examine the therapeutic effects of adenoviral-mediated gene transfer of IFN-γ into a mouse model of an established metastatic brain tumor. Temperature-sensitive replication- defective adenovirus was generated for gene transfer of IFN-γ (AdIFN) and β-galactosidase (AdBGAL) cDNAs in vivo. In this model, treatment with AdIFN elicits prolonged survival times and brain tumor rejection. Evidence against an immune-mediated response accounting for this result include: 1) absence of a memory immune response upon challenge, 2) lack of antitumor effects at sites distal to inoculation of AdIFN, and 3) preservation of the therapeutic effects of AdIFN in scid and beige mice and in inducible NO synthase (iNOS) knockouts. High concentrations of IFN-γ do not inhibit tumor growth in vitro making it unlikely that the antitumor effect of this treatment acts directly on the growth of the tumor cells. However, gene transfer of IFN-γ inhibits neovascularization of the tumor in a 3LL-Matrigel assay in vivo, and AdIFN induces apoptosis of endothelial cells in vivo, supporting the idea that AdIFN represses tumor growth by inhibiting angiogenesis. The substantial non- immune-mediated therapeutic benefits of AdIFN in animals paves the way for devising novel strategies for treating human brain tumors.",
author = "Fathallah-Shaykh, {Hassan M.} and Zhao, {Li Juan} and Kafrouni, {Abdallah I.} and Smith, {George M.} and James Forman",
year = "2000",
month = "1",
day = "1",
language = "English (US)",
volume = "164",
pages = "217--222",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "1",

}

TY - JOUR

T1 - Gene transfer of IFN-γ into established brain tumors represses growth by antiangiogenesis

AU - Fathallah-Shaykh, Hassan M.

AU - Zhao, Li Juan

AU - Kafrouni, Abdallah I.

AU - Smith, George M.

AU - Forman, James

PY - 2000/1/1

Y1 - 2000/1/1

N2 - The experiments in this paper were designed to examine the therapeutic effects of adenoviral-mediated gene transfer of IFN-γ into a mouse model of an established metastatic brain tumor. Temperature-sensitive replication- defective adenovirus was generated for gene transfer of IFN-γ (AdIFN) and β-galactosidase (AdBGAL) cDNAs in vivo. In this model, treatment with AdIFN elicits prolonged survival times and brain tumor rejection. Evidence against an immune-mediated response accounting for this result include: 1) absence of a memory immune response upon challenge, 2) lack of antitumor effects at sites distal to inoculation of AdIFN, and 3) preservation of the therapeutic effects of AdIFN in scid and beige mice and in inducible NO synthase (iNOS) knockouts. High concentrations of IFN-γ do not inhibit tumor growth in vitro making it unlikely that the antitumor effect of this treatment acts directly on the growth of the tumor cells. However, gene transfer of IFN-γ inhibits neovascularization of the tumor in a 3LL-Matrigel assay in vivo, and AdIFN induces apoptosis of endothelial cells in vivo, supporting the idea that AdIFN represses tumor growth by inhibiting angiogenesis. The substantial non- immune-mediated therapeutic benefits of AdIFN in animals paves the way for devising novel strategies for treating human brain tumors.

AB - The experiments in this paper were designed to examine the therapeutic effects of adenoviral-mediated gene transfer of IFN-γ into a mouse model of an established metastatic brain tumor. Temperature-sensitive replication- defective adenovirus was generated for gene transfer of IFN-γ (AdIFN) and β-galactosidase (AdBGAL) cDNAs in vivo. In this model, treatment with AdIFN elicits prolonged survival times and brain tumor rejection. Evidence against an immune-mediated response accounting for this result include: 1) absence of a memory immune response upon challenge, 2) lack of antitumor effects at sites distal to inoculation of AdIFN, and 3) preservation of the therapeutic effects of AdIFN in scid and beige mice and in inducible NO synthase (iNOS) knockouts. High concentrations of IFN-γ do not inhibit tumor growth in vitro making it unlikely that the antitumor effect of this treatment acts directly on the growth of the tumor cells. However, gene transfer of IFN-γ inhibits neovascularization of the tumor in a 3LL-Matrigel assay in vivo, and AdIFN induces apoptosis of endothelial cells in vivo, supporting the idea that AdIFN represses tumor growth by inhibiting angiogenesis. The substantial non- immune-mediated therapeutic benefits of AdIFN in animals paves the way for devising novel strategies for treating human brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=0033957424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033957424&partnerID=8YFLogxK

M3 - Article

C2 - 10605014

AN - SCOPUS:0033957424

VL - 164

SP - 217

EP - 222

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 1

ER -